UBS analyst John Sourbeer downgraded Catalent to Neutral from Buy with a price target of $63.50, up from $58, after the company entered into a merger agreement under which Novo Holdings will acquire Catalent in an all-cash transaction that values Catalent at $16.5B or $63.50 per share.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CTLT:
- M & A News: Novo Nordisk Announces $16.5B Catalent (NYSE:CTLT) Deal
- Catalent price target raised to $58 from $55 at RBC Capital
- Catalent Shareholders Approve Key Proposals at Annual Meeting
- Catalent’s 2023 Shareholder Meeting Approves Incentive Plan Amendment
- Early notable gainers among liquid option names on January 26th
